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hepatocellular carcinoma via inhibition of
gankyrin/stat3/akt pathway
Xuan Song1†, Jiabei Wang1†, Tongsen Zheng1†, Ruipeng Song1, Yingjian Liang1, Nishant Bhatta1, Dalong Yin1,
Shangha Pan1, Jiaren Liu2, Hongchi Jiang1,3* and Lianxin Liu1,3*Abstract
Background: Gankyrin has shown to be overexpressed in human liver cancers and plays a complex role in
hepatocarcinogenesis. Panobinostat (LBH589), a new hydroxamic acid-derived histone deacetylase inhibitor has
shown promising anticancer effects recently. Here, we investigated the potential of LBH589 as a form of treatment
for hepatocellular carcinoma (HCC).
Methods: Gankyrin plasmid was transfected into HCC cells, and the cells were selected for more than 4 weeks by
incubation with G418 for overexpression clones. The therapeutic effects of LBH589 were evaluated in vitro and in vivo.
Cell proliferation, apoptosis, cell cycle, invasive potential, and epithelial-mesenchy-mal transition (EMT) were examined.
Results: LBH589 significantly inhibited HCC growth and metastasis in vitro and in vivo. Western blotting analysis
indicated that LBH589 could decrease the expression of gankyrin and subsequently reduced serine-phosphorylated Akt
and tyrosine-phosphorylated STAT3 expression although the total Akt and STAT3 were unaffected. LBH589 inhibited
metastasis in vitro via down-regulation of N-cadherin, vimentin, TWIST1, VEGF and up-regulation of E-cadherin. LBH589
also induced apoptosis and G1 phase arrest in HCC cell lines. Ectopic expression of gankyrin attenuated the effects of
LBH589, which indicates that gankyrin might play an important role in LBH589 mediated anticancer effects. Lastly,
in vivo study indicated that LBH589 inhibited tumor growth and metastasis, without discernable adverse effects
comparing to control group, with abrogating gankyrin/STAT3/Akt pathway.
Conclusions: Our results suggested that LBH589 could inhibit HCC growth and metastasis through down-regulating
gankyrin/STAT3/Akt pathway. LBH589 may present itself as a novel therapeutic strategy for HCC.
Keywords: Hepatocellular carcinoma, LBH589, Apoptosis, Gankyrin, STAT3Introduction
Hepatocellular carcinoma ranks among the most common
malignancies in Asia and the third most frequent cause of
cancer death worldwide [1,2]. Although there are several
modalities of HCC treatment, most patients present
with unresectable tumors, and nonsurgical treatments* Correspondence: san3mudeepwhite@163.com; liulianxin@ems.hrbmu.edu.cn
†Equal contributors
1Department of Hepatic Surgery, The First Affiliated Hospital of Harbin
Medical University, Key Laboratory of Hepatosplenic Surgery, Ministry of
Education, 150001 Harbin, Heilongjiang Province, China
3Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Department
of General Surgery, The First Affiliated Hospital of Harbin Medical University,
No. 23 Youzheng Street, 150001 Harbin, Heilongjiang Province, China
Full list of author information is available at the end of the article
© 2013 Song et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orare minimally effective at the most. Given the grim outlook
of HCC, novel therapeutic targets and new modalities of ef-
fective chemoprevention and treatment is highly awaited.
Now there is a growing evidence indicating that epi-
genetic and genetic changes are crucial for the onset
and progression of malignant disease [3]. Many of the
changes in gene expression resulting in malignant
transformation result from altered epigenetic regulation
including DNA methylation and histone deacetylation
[4,5]. The histone deacetylase (HDAC) enzymes control
the structural conformation of chromatin via deacetylation
of core nucleosomal histones [6]. HDACs can close
chromatin, so transcription factors cannot access DNA
furthermore suppressing gene expression. In addition totd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proteins involved in the regulation of cell survival and pro-
liferation, angiogenesis, inflammation, and immunity.
The deacetylase inhibitors are a structurally diverse
class of targeted anticancer agents that have shown
in vitro and in vivo preclinical activity. Among these, the
deacetylase inhibitor panobinostat, (LBH589, Novartis
Pharmaceuticals, Basel, Switzerland) is the most widely
studied. The extensive pharmacokinetic, pharmacody-
namic and dose-findings are available for a wide variety
of hematologic and solid malignancies which obviously
gives superiority over others. It belongs to the structur-
ally novel cinnamic hydroxamic acid class of compounds
and is currently in clinical development for both intra-
venous and oral formulation [7].
Gankyrin, Fujita et al. using complementary DNA sub-
tractive hybridization found a seven ankyrin-repeat pro-
tein [8]. It was initially characterized as an oncoprotein
commonly overexpressed in hepatocellular carcinoma
and independently as a protein associated with the 19S
regulatory complex of the 26S proteasome. Furthermore,
inhibition of gankyrin could induce apoptosis in cancer
cells, especially in liver cancer cells [1]. Gankyrin gene is
also one of the important genes over-expressed in a
rodent model of hepatocarcinogenesis [9]. Therefore,
gankyrin is a promising target for potential anti-liver
cancer therapeutic agents.
Against this background, we hypothesize that LBH589
might be used as a promising modality for HCC treat-
ment. In the present study, we sought to evaluate the
therapeutic potency of LBH589 toward HCC by in vivo
and in vitro experiments. We extensively investigated the
function of LBH589 and determined its contribution to in-
hibit HCC proliferation and metastasis. We also elucidated
the molecular mechanisms by which LBH589 inhibits
tumor proliferation and metastasis. Results presented here
suggest that gankyrin/STAT3/Akt pathway plays an im-
portant role in the treatment of LBH589. We propose that
LBH589 is a new powerful chemotherapeutic for HCC.
Materials and methods
Cell lines and LBH589 treatment
Liver cancer cell lines SMMC-7721 and HCC-LM3 were
purchased from Cell Bank of Type Culture Collection of
Chinese Academy of Sciences, Shanghai Institute of Cell
Biology, Chinese Academy of Sciences; HepG2 cell line
was obtained from American Type Culture Collection
(Manassas, VA). HCC-LM3, HepG2 and SMMC-7721
cell lines were maintained at 37°C in a humidified incu-
bator containing 5% CO2, in Dulbecco’s Modified Eagle
Medium supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin. LBH589 was provided
by Novartis Pharmaceuticals, Inc. (East Hanover, NJ).
LBH589 was dissolved in DMSO (Sigma, St. Louis, MO)and stored as a 30 mmol/L stock solution in small ali-
quots at −20°C.
MTT assay
HCC cells were seeded at 2 × 104 per well in 96-well
flat-bottomed plates and incubated in 10% FBS sup-
plemented DMEM for 24 h. Cells were treated with
LBH589 at various concentrations in the same medium.
Controls received DMSO vehicle at a concentration
equal to that in drug-treated cells. After 24, 48 and 72 h,
the drug-containing medium was replaced with 200 μL of
10% FBS supplemented DMEM containing 0.5 mg/mL
MTT, and cells were incubated in the CO2 incubator at
37°C for 4 h. Medium was removed, the reduced MTT
was solubilized in 100 μL per well of DMSO, and mea-
sured absorbance at 570 nm.
Plasmid construction and transfection
For gankyrin overexpression, The whole cDNA sequence
of gankyrin (from pCMV-HA-gankyrin) was cloned into
the pCDNA-3.1A-myc vector and obtained myc-gankyrin
construct. pCMV-HA-gankyrin and pCDNA-3.1A-myc
were purchased from Biowot Technologies (Shenzhen,
China). Control plasmid and myc-gankyrin were transfected
into HCC cells using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) following the manufacturer’s protocol. The
cells were selected for more than 4 weeks by incubation
with G418 (Invitrogen, 400 ng/ml for SMMC-7721 and
600 ng/ml for HCC-LM3 and HepG2) for overexpression
clones. Stable single clones were selected and myc expres-
sion assessed using western blotting. Transient trans-
fection of pCMV-HA-gankyrin and the control constructs
into HCC cells were performed using Lipofectamine 2000.
RNA interference
Gankyrin-specific shRNA, synthesized by GeneChem Cor-
poration (Shanghai, China), was designed to silence all
splices of human gankyrin mRNA. The sequence was:
forward, 5′- Ccggca GGT TGG TCT CCT CTT CAT AT
T CAA GAG ATA TGA AGA GGA GAC CAA CC
tgTTTTTg-3′; reverse, 5′-aattcaaaaaca GGT TGG TCT
CCT CTT CAT ATC TCT TGA ATA TGA AGA GGA
GAC CAA CC tg-3′. It was scrambled to generate a nega-
tive control. Lentivirus vectors expressing shRNA targeting
gankyrin (Lenti-shgankyrin) was constructed, packed, and
purified by GeneChem Corporation (Shanghai, China).
Cell cycle and apoptosis analysis
Cell cycle analysis kit and Annexin V–FITC apoptosis
kit were purchased from Becton Dickinson, San Diego,
CA. For cell cycle analysis, the cells were harvested after
treatment, fixed with ice-cold 70% ethanol solution, hy-
drolyzed with 250 μg/ml of RNaseA at 37°C for 30 min,
and stained with propidium iodide at 10 mg/ml for 20 min.
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meter (Becton Dickinson, San Diego, CA).
For apoptosis analysis, the cells were harvested after
treatment, washed twice with pre-chilled PBS and
resuspended in 1x binding buffer at a concentration of
1 × 106 cells/ml. 100 μl of such solution (1 × 105 cells)
was mixed with 5 μl of Annexin V-FITC and 5 μl of
propidium iodide according to the manufacturer’s in-
struction. The mixed solution was gently vortexed and
incubated in the dark at room temperature (25°C) for
15 min. 400 μl of 1x dilution buffer was then added to
each tube and cell apoptosis analysis was performed by
FACSCalibur flow cytometer within 1 hour.
Western blotting
For preparing total cell lysates, cells were lysed in lysis
buffer (Invitrogen), incubated on ice for 30 min and
centrifuged for 20 min to remove cell debris. Total cell
lysate was subjected to SDS–polyacrylamide gel electro-
phoresis. The proteins were then electro-transferred to
polyvinylidene difluoride membrane (Millipore, Billerica,
MA) and incubated overnight with antibodies at 4°C.
Subsequently, the membranes were incubated with sec-
ondary antibodies for 1 hour at room temperature and
the signal was detected using an enhanced chemilumin-
escence detection kit (Pierce, Rockford, IL). The primary
antibodies were acetyl-Histone H3, acetyl-Histone H3
(Lys27) and acetyl-Histone H4 were purchased from
Millipore. Histones were isolated according to the in-
struction of the manufacturer. STAT3, p27, HA-tag,
myc-tag, p-STAT3 (Tyr705), Akt, p-Akt (Ser473), PI3K,
p-PI3K (Tyr458), JAK2, p-JAK2 (Tyr1007/1008), Bcl-xL,
cleaved-PARP, cleaved-caspase-3, 8 and 9 were pur-
chased from Cell Signaling Technology (Danvers, MA).
CD31 was purchased from Novus (Littleton, CO). Ki-67,
N-cadherin, E-cadherin and vimentin were purchased
from Abcam (Cambridge, MA). Gankyrin, p16, p53, Rb,
VEGF, cyclinD1, cyclinE, tubulin and β-actin were pur-
chased from Santa Cruz Biotechnology (Dallas, Texas).
The secondary antibodies, anti-mouse IgG-HRP and
anti-rabbit IgG-HRP were purchased from Santa Cruz
Biotechnology.
Interleukin-6 (IL-6) determination
Detection and quantitative measurement of human IL-6
in cell culture supernatants were performed by the Hu-
man IL-6 ELISA kit (R&D Systems, Minneapolis, MN)
following the manufacturer’s instructions.
Immunofluorescence
Briefly, cells seeded on coverslips were fixed with 4%
(w/v) paraformaldehyde (Sigma) for 10 min and
permeabilized with 0.1% (v/v) Triton X-100 for 5 min
at room temperature. The cells were then incubatedovernight with primary antibodies at 4°C, followed by in-
cubation with fluorescent secondary antibody (invitrogen)
for 1 hour at room temperature. After final washes with
PBS, the coverslips were mounted using an anti-fade moun-
ting solution containing 4′,6-diamidino-2-phenylindole
(DAPI; Vector lab, Burlingame, CA) and images were
examined and captured.
Cell invasion assay
Invasion was measured by using 24-well BioCoat cell
culture inserts (BD Biosciences, NJ) with an 8-μm–
porosity polyethylene terephthalate membrane coated
with Matrigel Basement Membrane Matrix.
Nude mice orthotopic model study
The study was approved by the committee on the use of
live animals in teaching and research of the Harbin Medical
University, Harbin, China. Experiments were started after
1 week of acclimatization. For assessment of LBH589 in-
hibits the proliferation of HCC-LM3 tumors in orthotopic
tumor xenografts, an orthotopic liver tumor model in nude
mice was established. Briefly, we used HCC-LM3, HCC-
LM3 (which transfected with gankyrin) and HCC-LM3
(which transfected with vector ctrl) cells. Then these ap-
proximately 1 × 107 HCC-LM3 cells in 0.2 ml culture
medium phosphate buffered saline (PBS) were injected sub-
cutaneously into the right flank of the mice, which were
then observed daily for signs of tumor development. Once
the subcutaneous tumor reached 1–1.5 cm in diameter, it
was removed and cut into about 1–2 mm3 cubes which
were implanted into the left liver lobe of another group of
nude mice. Animals were randomized to receive either
LBH589 (10 mg/kg/d, i.p.) or vehicle (saline solution with
5% DMSO and 1% Tween 80) at 1 week after implantation.
Liver tumors were harvested for experiment at 5 weeks
after tumor implantation. Tumor volume was calculated as
below: V (cm3) = width2 (cm2) × length (cm) /2.
In vivo metastasis analysis
HepG2, HepG2 (which transfected with gankyrin) and
HepG2 (which transfected with vector ctrl) cells (1 × 106/
0.2 ml) were injected into nude mice by way of tail vein to
imitate tumor metastasis. Experimental animals (n = 8/
group) received either LBH589 (10 mg/kg/d, i.p.) or ve-
hicle (saline solution with 5% DMSO and 1% Tween 80)
five times per week beginning on the day of implantation.
The mice were killed 5 weeks after the inoculation and
lungs were removed and fixed in formaldehyde. The lung
metastases were confirmed by H&E staining.
Immunohistochemistry analysis
Immunohistochemistry was performed as described pre-
viously [10] using Ki-67, cleaved-caspase-3, CD31, E-
cadherin, N-cadherin and vimentin antibodies. In brief,
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with ethanol. Tissue sections were then preincubated
with 10% normal goat serum in PBS (pH 7.5) followed
with incubation with primary antibody overnight at 4°C.
Tissue sections were then stained with biotinylated
secondary antibody (Vector lab) for 1 hour at room
temperature, followed by the Vectastain Elite ABC reagent
(Vector lab) for 30 min. The peroxidase reaction was de-
veloped with diaminobenzidine (DAB kit; Vector lab) and
the slides were counterstained with hematoxylin.
Statistical analysis
All the data are expressed as mean values ± standard de-
viation (SD). Comparisons among multiple groups were
made with a one-way analysis of variance (ANOVA)
followed by Dunnet t-test. “p <0.05′ was used for statis-
tical significance.
Results
LBH589 is a potent anti-HCC agent and induces histone
acetylation and apoptosis in HCC cells
Exposure of HCC-LM3, HepG2 and SMMC-7721 cells
to LBH589 for 24, 48 and 72 hours resulted in a signifi-
cant growth inhibition (Figure 1A). To verify whether
LBH589 induces hyperacetylation of histones in HCC
cells with different concentrations of LBH589 (50 and
100 nM) for 24 h, acetylation of histone H3, histone H3
(Lys27) and histone H4 were analyzed by western blot-
ting. Results suggest that HCC cells exhibited a progres-
sive increase in histone H3, histone H3 (Lys27) and
histone H4 acetylation correlating with LBH589 dose of
treatment (Figure 1B).
To determine whether HCC cell death induced by
LBH589 involves apoptosis, flow cytometric analysis
with annexin V–PI staining was performed. LBH589 in-
duced apoptosis in all HCC cell lines tested in the dose
of 50 nM (Figure 1D). Figure 1E is a representative ex-
ample of apoptosis of HepG2 cell line treated with 50
nM of LBH589 at 48 h.
LBH589 decreases gankyrin and induces cell death in a
caspase-dependent manner by cleavage of caspases 3, 8
and 9
Next we explored the effect of LBH589 on apoptotic path-
ways. LBH589 significantly decreased the expression of
gankyrin (Figure 1C), and induced cleavage of caspases 3,
8 and 9, as well as PARP, in a dose-dependent manner
after 24-hr incubation with the drug (Figure 1F). Figure 1C
showed the basal level of gankyrin in HCC-LM3 and
HepG2 was stronger than SMMC-7721. Additional file 1:
Figure S1A showed the invasive capability of HCC-LM3
and HepG2 was stronger than SMMC-7721 cell. In order
to determine the significance of gankyrin, we transfected
human gankyrin plasmid into HCC cells. Additional file 1:Figure S1B showed the expression of myc after se-
lection with G418. Gankyrin overexpression attenuated
the LBH589-induced apoptosis of HCC cells (Figure 1G).
Figure 1H is a representative example of apoptosis of
HepG2 cell line (which transfected human gankyrin/con-
trol plasmid) treated with 50 nM of LBH589 at 48 h.
Transient transfection of pCMV-HA-gankyrin also can
attenuate the LBH589-induced apoptosis of HCC cells
(Additional file 2: Figure S2B). Additional file 2: Figure
S2A showed the expression of HA after transient transfec-
tion of pCMV-HA-gankyrin.
LBH589 decreases the levels of p-STAT3 and p-Akt in HCC
cells, and gankyrin overexpression can attenuate the
effect of LBH589
We first evaluated the effect of LBH589 on the expression
of p-STAT3 and p-Akt in HCC cells. Figure 2A shows that
treatment of HCC cells with LBH589 for 24 h leads to a
significant reduction in serine-phosphorylated Akt expres-
sion as well as tyrosine-phosphorylated STAT3 although
total Akt and STAT3 were unaffected. Next, we examined
whether gankyrin overexpression could inhibit LBH589-
induced dephosphorylation of Akt and STAT3 in HCC cell
lines. As shown in Figure 2B, gankyrin overexpression ac-
tivated the expression of p-Akt and p-STAT3, and
LBH589 induced Akt and STAT3 dephosphorylation was
reduced by gankyrin overexpression. Gankyrin knockdown
also can decrease the expression of p-Akt and p-STAT3
(Additional file 3: Figure S3B). Additional file 3: Figure
S3A showed the expression of gankyrin after transfection
of Lenti-shgankyrin. The results indicate that gankyrin/
STAT3/Akt pathway is likely an important target of
LBH589 in HCC cells.
LBH589 downregulates Bcl-xL expression, and
overexpression of gankyrin partially protects against
LBH589-mediated inhibition of Bcl-xL
Next, we investigated Bcl-xL, one of the key regulators
of apoptosis in HCC cells is considered important for
HCC cell survival and drug resistance [11]. As shown in
Figure 2C, LBH589 treatment strongly downregulated
Bcl-xL expression in HCC cells. Furthermore, over-
expression of gankyrin using human gankyrin plasmid
partially protected against LBH589-induced inhibition of
Bcl-xL (Figure 2C), indicating that reduction in Bcl-xL
may contribute an important role in LBH589-induced
apoptosis in HCC cells.
LBH589 mediates p-Akt and p-STAT3 expression through
gankyrin/PI3K/Akt and gankyrin/Rb/IL-6/JAK2 pathways
Next, we investigated the expression of p53 and Rb,
which are the direct targets of gankyrin. After treatment
of LBH589, the expression of p53 increased in HepG2,
no obvious change was detected in HCC-LM3 and
Figure 1 (See legend on next page.)
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Figure 2 LBH589 decreases the levels of p-STAT3, p-Akt and Bcl-xL in HCC cells, and gankyrin overexpression can attenuate the effect
of LBH589. LBH589 mediates the expression of p-Akt and p-STAT3 through gankyrin/PI3K/Akt and gankyrin/Rb/IL-6/JAK2/STAT3 pathways. (A)
HCC cells were treated for 24 h with or without LBH589 and analyzed for the indicated protein by western blotting. (B) Western blotting results
showed LBH589 induced Akt and STAT3 dephosphorylation was reduced by gankyrin overexpression. (C) Western blotting results showed
LBH589 decreased Bcl-xL expression and overexpression of gankyrin partially protected against LBH589-induced inhibition of Bcl-xL. β-actin was
used as the internal control. All assays were done in triplicate. (D) LBH589 increased Rb expression and decreased the expression of PI3K, p-PI3K
(Tyr458), JAK2 and p-JAK2 (Tyr1007/1008) in three HCC cells. After treatment of LBH589, the expression of p53 increased in HepG2, no obvious
change was detected in HCC-LM3 and SMMC-7721 cells. β-actin was used as the internal control. All assays were done in triplicate. (E) After
treatment of LBH589, the level of IL-6 in three HCC cells was significantly decreased compared with controls. The results represent means ± SD of
experiments performed in triplicate. ***P < 0.001, LBH589 treated versus control group.
(See figure on previous page.)
Figure 1 LBH589 is cytotoxic to HCC cells in a dose- and time-dependent manner. (A) MTT assay showing percentage of viable HCC cells
treated with DMSO, 1, 5, 10, 50, 100 and 1000 nM of LBH589 for 24, 48 and 72 h. The results represent means ± SD of experiments performed in
triplicate. ***P < 0.001, LBH589 treated versus control group. (B) Expression of acetyl-Histone H3, acetyl-Histone H3 (Lys27) and acetyl-Histone H4
were determined via western blotting after treatment with 50 and 100 nmol/L LBH589 for 24 h. Tubulin was used as the internal control. All
assays were done in triplicate. (C) The expression of gankyrin after treatment with 50 and 100 nmol/L LBH589 for 24 h. β-actin was used as the
internal control. All assays were done in triplicate. (D) Flow cytometry results of annexin V-PI staining of HCC cells after exposure to DMSO or
LBH589 (50 nM) for 48 h. The results represent means ± SD of experiments performed in triplicate. ***P < 0.001, LBH589 treated versus DMSO
group. (E) A representative example of apoptosis of HepG2 cell line treated with 50 nM of LBH589 at 48 h is shown. (F) Expression of apoptosis
relative proteins were determined via western blotting after treatment with 50 and 100 nmol/L LBH589 for 24 h. β-actin was used as the internal
control. All assays were done in triplicate. (G) Flow cytometry results showed gankyrin overexpression attenuated the LBH589-induced apoptosis of
HCC cells. The results represent means ± SD of experiments performed in triplicate. ***P < 0.001, LBH589 + vector ctrl treated versus LBH589 + gankyrin
group. (H) A representative example of apoptosis of HepG2 cell line (which transfected human gankyrin/control plasmid) treated with 50 nM of
LBH589 at 48 h.
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sion of Rb increased in three HCC cells (Figure 2D). To
further elucidate how LBH589 mediate p-Akt and p-
STAT3 through gankyrin. We detected the effect of
LBH589 on P13K and JAK2 expression. The expression of
p-PI3K (Tyr458) and PI3K decreased after LBH589 treat-
ment in three HCC cells (Figure 2D), which results in in-
hibition of p-Akt activity (Figure 2A). This result suggests
a mechanism in which LBH589 inhibits p-Akt signaling
through control of the gankyrin/PI3K/Akt pathway.
Santhanam et al. and Zhu et al. reported that Rb can
decrease the interleukin-6 (IL-6) level [12,13]. and IL-
6 can increase the expression of p-STAT3. LBH589 in-
creased the expression of Rb in three HCC cells, and
then we detected the levels of IL-6 in supernatant
decreased in three HCC cells (Figure 2E). Western
blotting showed the expression of p-JAK2 (Tyr1007/
1008) and JAK2 decreased after LBH589 treatment
(Figure 2D). And gankyrin knockdown also can de-
creased the levels of IL-6 (Additional file 3: Figure
S3C). So the results suggest LBH589 inhibits p-STAT3
through gankyrin/Rb/IL-6/JAK2 pathway.
LBH589 inhibits invasive potential of HCC cells in vitro
To determine the function of LBH589, we treated
HCC-LM3 and HepG2 with LBH589. LBH589 sig-
nificantly inhibited their invasive capacity by 2.9- and
2.5-fold, as compared with DMSO-treated cells
(Figure 3A). In contrast, gankyrin overexpression in
HCC-LM3 and HepG2 cells attenuated the LBH589-
induced inhibition of invasion (Figure 3A). Transient
transfection of pCMV-HA-gankyrin also can attenuate
the LBH589-induced inhibition of invasion (Additional
file 2: Figure S2C). Given that LBH589 inhibits HCC inva-
sion, we investigated the effect of LBH589 on epithelial-
mesenchymal transition (EMT), a critical event in
tumor invasion. Western blotting detected higher
expression of E-cadherin in HCC-LM3 and HepG2
cells treated with LBH589. In contrast, the expression
of N-cadherin, vimentin, VEGF and TWIST1 decreased
in LBH589 treated HCC-LM3 and HepG2 cells
(Figure 3B). Overexpression of gankyrin abrogated the ef-
fect of LBH589-induced reduction of EMT (Figure 3B).
As shown by immunofluorescence (Figure 3C), LBH589
markedly reduced N-cadherin and vimentin levels in
both HCC-LM3 and HepG2 cells. Overexpression of
gankyrin abrogated the effect of LBH589-induced
reduction of N-cadherin and vimentin, which was in
conjunction with the results in Figure 3B. The immu-
nofluorescence results for E-cadherin are shown in
Additional file 4: Figure S4, LBH589 markedly increased
E-cadherin level in both HCC-LM3 and HepG2 cells.
Overexpression of gankyrin abrogated the effect of
LBH589-induced induction of E-cadherin.LBH589 increases p16 and p27 expression, downregulates
cyclin D1 and induces G1 cell cycle arrest in HCC cells
To further investigate the effect of LBH589 on cell cycle
distribution in HCC cells, HCC cells were incubated with
50 nM LBH589 for 48 h. The FACs analysis revealed a
more distinguished decrease in the number of cells in S
phase at 48 h compared with DMSO group (Figure 4A).
The data here suggested that the cell cycle was blocked at
G0/G1 checkpoint more significantly. Figure 4B is a repre-
sentative example of cell cycle arrest of HepG2 cell line
treated with 50 nM of LBH589 at 48 h.
We investigated the effect of LBH589 on their expres-
sion as the cell cycle promoter cyclin D1 and cyclin E are
key regulators of G1 phase. Shown in Figures 4C, we ob-
served a reduction in cyclin D1 and E after treated with
LBH589 for 24 h. As increased expression of p27 results
in inhibition of proliferation, we examined the effect of
LBH589 on p27 expression and that of p16, another cell
cycle inhibitor that has been shown to be transcriptionally
silenced in HCC [14]. Expression of both p27 and p16
proteins was induced by LBH589 after 24 h (Figure 4C).
In order to determine the significance of gankyrin,
we transfected human gankyrin plasmid into HCC
cells. Gankyrin overexpression attenuated the LBH589-
induced G0/G1 phase arrest of HCC cells (Figure 4D).
Figure 4E is a representative example of cell cycle arrest of
HepG2 cell line (which transfected human gankyrin/con-
trol plasmid) treated with 50 nM of LBH589 at 48 h.
Transient transfection of pCMV-HA-gankyrin also can at-
tenuate the LBH589-induced G0/G1 phase arrest of HCC
cells (Additional file 2: Figure S2D).
LBH589 inhibits localized growth and metastasis of HCC
in vivo
We further examined the effect of LBH589 on HCC
growth by establishing an orthotopic liver tumor model
in nude mice, and examined the effect of LBH589 on
pulmonary metastasis by injecting HCC cells through
tail vein to imitate tumor metastasis. HCC-LM3 and
HepG2 cells were used for in vivo studies. Compared to
DMSO groups, LBH589 treatment resulted in significant
decrease of tumor size, the number of pulmonary meta-
static foci and average size of pulmonary metastatic le-
sions (Figure 5A-B). Furthermore, the orthotopic liver
tumor model and pulmonary metastasis model based on
HCC-LM3 and HepG2 cells also showed that gankyrin
overexpression attenuated the effect of LBH589-induced
reduction of tumor cell proliferation and lung metastasis
(Figure 5A-B). The IHC analysis showed the changes of
Ki-67, cleaved-caspase-3, CD31, E-cadherin, N-cadherin
and vimentin in different group (Figure 5C). The expres-
sion of relative proteins mentioned above were also ana-
lyzed by western blotting in different group (Figure 5D).
Together, these results reveal functional significance of
Figure 3 LBH589 inhibits invasive potential of HCC cells in vitro. (A) Cell invasion experiment results showed LBH589 significantly inhibited
the invasive capacity of HCC-LM3 and HepG2 cells, and gankyrin overexpression attenuated the LBH589-induced inhibition of invasion in
HCC-LM3 and HepG2 cells. ***P < 0.001. The results represent means ± SD of experiments performed in triplicate. (B) Western blotting showed
LBH589 increased the expression of E-cadherin and decreased the expression of N-cadherin, vimentin, VEGF and TWIST1 in HCC-LM3 and HepG2
cells. Overexpression of gankyrin abrogated the effect of LBH589-induced reduction of EMT and angiogenesis. β-actin was used as the internal
control. All assays were done in triplicate. (C) Single and merged images were taken to show immunofluorescence staining of N-cadherin (green)
and vimentin (red) accompanied by the cell nucleus (blue) stained by DAPI.
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metastasis in HCC and in aggressive tumors.
Discussion
HCC is one of the most difficult cancer to treat, largely due
to the advanced stage by the time it is diagnosed and poor
response to treatment, and its incidence is rising in in-
dustrialized nations. Improvement in both chemopreven-
tion and treatment of HCC is sorely needed. As a new class
of chemotherapeutic agents, HDACi have demonstrated
potent anticancer activities in preclinical studies and arecurrently in various stages of clinical development. LBH589
(Novartis Pharma AG) is a hydroxamic acid derivative,
which has been reported to possess cytotoxic properties
against different human cancers in vivo and in vitro
[15-17]. But the exact final pathways that lead to the anti-
cancer effects observed still remain to be fully elucidated.
Given the fact that liver is well protected HCC by the
tumor suppressor proteins p53, Rb and C/EBPα, it could
be assumed that the development of HCC might include
activation of a powerful system for the elimination of
these proteins. During the examination of early events in
Figure 4 Effect of LBH589 on cell cycle proteins and cell cycle progression. (A) Cell cycle analysis in LBH589 treated HCC cells showing arrest in
G1 phase. The results represent means ± SD of experiments performed in triplicate. ***P< 0.001, LBH589 treated versus control group. (B) A representative
example of cell cycle arrest of HepG2 cell line treated with 50 nM of LBH589 at 48 h. (C) LBH589 induces expression of p16 and p27 and reduces
expression of cyclin D1 and cyclin E. β-actin was used as the internal control. All assays were done in triplicate. (D) Gankyrin overexpression attenuated the
LBH589-induced G0/G1 phase arrest of HCC cells. ***P< 0.001, the results represent means ± SD of experiments performed in triplicate. (E) A
representative example of cell cycle arrest of HepG2 cell line (which transfected human gankyrin/control plasmid) treated with 50 nM of LBH589 at 48 h.
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HCC, gankyrin has been identified as a candidate for this
important role [18]. The studies of gankyrin-dependent
promotion of liver cancer have indicated that gankyrin
could not only bind to mdm2 and enhance degradation of
p53 but also interact with Rb to reduce its stability.Gankyrin could also bind to CDK4 and replaces p16 from
CDK4, leading to the activation of CDK4 [19,20]. Against
the significant role of each of these proteins in protection
of liver from HCC, one could assume the elevation of
gankyrin might be a key step in the release of growth in-
hibitory control of the liver and in development of liver
Figure 5 LBH589 inhibits proliferation and metastasis of HCC in vivo. (A) Photomicrographs were taken for liver tumors in nude mice,
5 weeks after orthotopic xenograft transplantation of HCC-LM3, vector ctrl transfected or gankyrin transfected HCC-LM3 cells. Representative
images of a mouse in each group were presented. Tumor volumes from each group were measured as described in Materials and Methods.
(B) Representative lung tissue sections from each group were shown (hematoxylin and eosin stain; magnification, × 100). The number of lung
metastatic foci in each group was calculated. (C) Tumors from different groups were immunostained for indicated molecules. CD31-stained
microvessels were counted to record microvessel density; Apoptosis cells were counted to give the apoptosis index; and cells expressing Ki-67
were counted to calculate the proliferation index. Pictures are representative of three independent experiments. Black scale bars, 100 μm.
(D) Western blotting was performed to detect expression of indicated molecules in tumor samples. β-actin was used as the internal control.
All assays were done in triplicate. *P < 0.05, the results expressed as means ± SD of three independent experiments.
Song et al. Molecular Cancer 2013, 12:114 Page 10 of 13
http://www.molecular-cancer.com/content/12/1/114cancer. We, therefore, investigated the effects of a novel
HDACi, LBH589, in HCC cell lines. We show that LBH589
has a significant inhibitory effect on gankyrin/STAT3/Akt
signaling and EMT, downregulating the expression of
gankyrin and blocking phosphorylation of STAT3 and Akt,
thereby inducing inhibition of proliferation and metastasis.
We presume that LBH589 mediates the expression of
gankyrin from transcriptional level (e.g. we presume thatLBH589 enhances the activity of farnesoid X receptor
(FXR), through which the expression of gankyrin can be
inhibited at transcriptional level [21]) either from transla-
tional level (e.g. we presume that LBH589 inhibits the ex-
pression of hepatoma upregulated protein (HURP), HURP
inhibition can activate the MDM2-mediated ubiquitination
and degradation of gankyrin [22].), or from both transcrip-
tional and translational level simultaneously. But the exact
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the future. To explore how LBH589 blocks phosphoryl-
ation of STAT3 and Akt, we performed western blotting
to detect the expression of PI3K, Rb and JAK2 after
LBH589 treatment. And we detected the levels of IL-6 in
supernatant in three HCC cells after LBH589 treatment.
The results showed LBH589 inhibits the expression of p-
Akt through gankyrin/PI3K/Akt pathway. And LBH589
inhibits p-STAT3 through gankyrin/Rb/IL-6/JAK2/STAT3
pathway. After treatment of LBH589, the expression of
p53 increased in HepG2, no obvious change was detected
in HCC-LM3 and SMMC-7721 cells. So we think LBH589
inhibits the proliferation and metastasis of HCC is p53 in-
dependent. The potential mechanisms of LBH589 are
summarized in Figure 6.
LBH589 also decreases the expression of cyclin D1, cyc-
lin E, Bcl-xL, N-cadherin, vimentin, VEGF and TWIST1,
the major downstream targets of STAT3 and Akt. LBH589
upregulates the expression of p27 and p16, then inhibits
cell cycle progression. And overexpression of gankyrin
partly protects against LBH589-induced HCC cell death
and metastatic inhibition. Finally, LBH589 inhibits local-
ized growth and metastasis of HCC in vivo.Figure 6 The proposed mechanisms by which LBH589 exerts
its effects.Our MTT assay demonstrated that the LBH589 could
induce a dramatic cell viability reduction in all the
three HCC cell lines tested. After cells were treated
with LBH589 for 48 hours, we observed a significant
decrease of S-phase population. FACS analysis also
showed that the growth inhibitory effect by LBH589
was also related to induction of apoptosis in HCC cells.
Using western blotting assay, we found that gankyrin
was decreased significantly after LBH589 treatment.
To evaluate the essentiality of gankyrin in LBH589 me-
diated growth inhibition, human gankyrin plasmid was
transfected into HCC cells. After transfection, we found
HCC cells with high-level gankyrin can significantly attenu-
ate the cell growth inhibitory effect of LBH589. Therefore,
we propose that gankyrin might contribute, at least par-
tially, to LBH589 induced tumor growth inhibition.
The mechanisms of HDACi-induced cytotoxicity may
vary depending on the class of HDAC being inhibited
and the downstream targets of HDAC in different cancer
cells. Our results in HCC show that LBH589-induced
apoptosis is associated with cleavage of caspases 3, 8 and
9, and PARP cleavage. Further, LBH589-induced apoptosis
is in large part dependent on caspase activation. In HCC
cells, LBH589 also modulates the expression of the
antiapoptotic proteins. The expression of Bcl-xL was sig-
nificantly reduced, and overexpression of gankyrin can at-
tenuate the LBH589-induced inhibition of Bcl-xL.
We further demonstrate that incubation of HCC cells
with LBH589 leads to the loss of N-cadherin and vimentin
and accumulation of E-cadherin, and LBH589 significantly
inhibited the invasive capacity of HCC cells. Conversely,
gankyrin overexpression attenuates LBH589-induced
metastatic inhibition. We think that these results might
apply to a number of additional cancer types other than
HCC because gankyrin is frequently upregulated in many
other cancer types as well [23-26].
The effect of LBH589 on HCC proliferation, invasion
and metastasis was also directly demonstrated in our
in vivo studies. In orthotopic xenografts and in vivo me-
tastasis analysis, LBH589 group generated smaller pri-
mary tumors and fewer lung metastasis foci, indicating
LBH589 inhibited aggressive and metastatic properties
of HCC. Moreover, up-regulation of gankyrin led to se-
vere inhibition of LBH589-induced suppression of tumor
growth and lung metastasis of HCC in mice. To our
knowledge, this is the first report that gankyrin is critical
for LBH589 to inhibit HCC metastasis, in addition to
tumor suppression, proliferation and growth.
Conclusions
In conclusion, we have demonstrated for the first time
that LBH589 could inhibit expression of gankyrin and
metastasis in different HCC cell lines. LBH589 induced
cell cycle arrest and apoptosis in vitro and inhibited
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http://www.molecular-cancer.com/content/12/1/114tumor growth and metastasis in a nude mice model. Its
ability to target mainly the gankyrin/STAT3/Akt cellular
pathway suggests its viability as part of the therapeutic
armamentarium for HCC. Our results provide preclinical
rationale for clinical development of LBH589 for HCC.
Additional files
Additional file 1: Figure S1. The invasive capability of three HCC cells
in vitro. (A) Cell invasion assay was performed in the indicated cells. Data
are presented as mean ± SD from three independent experiments.
***P < 0.001. (B) The levels of myc after selection with G418. β-actin was
used as the internal control. All assays were done in triplicate.
Additional file 2: Figure S2. Transient transfection of pCMV-HA-gankyrin
can attenuate the effect of LBH589. (A) The expression of HA after transient
transfection of pCMV-HA-gankyrin in three HCC cells. β-actin was used as
the internal control. All assays were done in triplicate. (B) Flow cytometry
results showed transient transfection of gankyrin attenuated the LBH589-
induced apoptosis of HCC cells. The results represent means ± SD of
experiments performed in triplicate. ***P < 0.001, LBH589 + vector ctrl
treated versus LBH589 + HA-gankyrin group. (C) Cell invasion experiment
results showed transient transfection of gankyrin attenuated the LBH589-
induced inhibition of invasion in HCC-LM3 and HepG2 cells. ***P < 0.001.
The results represent means ± SD of experiments performed in triplicate.
(D) Transient transfection of Gankyrin attenuated the LBH589-induced G0/
G1 phase arrest of HCC cells. ***P < 0.001, the results represent means ± SD
of experiments performed in triplicate.
Additional file 3: Figure S3. Gankyrin knockdown can decrease the
levels of p-Akt, p-STAT3 and IL-6 in HCC cells. (A) The expression of
gankyrin after transfection of Lenti-shgankyrin. β-actin was used as the
internal control. All assays were done in triplicate. (B) The expression of
p-Akt and p-STAT3 decreased after transfection of Lenti-shgankyrin.
β-actin was used as the internal control. All assays were done in triplicate.
(C) After transfection of Lenti-shgankyrin, the level of IL-6 in three HCC
cells was significantly decreased compared with controls. The results
represent means ± SD of experiments performed in triplicate.
***P < 0.001, Lenti-shgankyrin group versus control group.
Additional file 4: Figure S4. Single and merged images were taken to
show immunofluorescence staining of E-cadherin (green) accompanied
by the cell nucleus (blue) stained by DAPI in HCC-LM3 and HepG2 cells.
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